Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood.
A 35 y old woman with severe and progressive systemic lupus erythematosus (SLE) received high-dose chemotherapy followed by a T cell depleted autologous stem cell transplantation. Peripheral blood stem cell were mobilised with Cyclophosphamide 4.5 g/m2 followed by Granulocyte-Colony Stimulating Factor (G-CSF). A CD34 positive selection provided a 3 log T cell depletion. High-dose immunosuppression consisted of the BEAM regimen. The purified autograft was reinfused on day 0. In the post transplant period, hemopoietic growth factors, G-CSF, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Erythropoietin, were administered, engraftment was rapid. Both the mobilisation and the transplant procedures were easily performed and well tolerated. One year later, the patient is in clinical remission. The ANA and anti-SSA-antibodies were undetectable at 1 and 6 months after intensification, but reappeared at low levels at 9 months. Corticosteroid requirement has gradually decreased. In conclusion, we report here the favourable evolution of a patient with a severe SLE, who clinically improved with high-dose immunosuppressive therapy and autologous stem cell transplantation, and showed a 9 month serological remission.
Fouillard
L
L
Department of Hematology, Hôpital Saint-Antoine, and Centre de Recherches Claude-Bernard sur la Thérapie Cellulaire, Paris, France.
Gorin
N C
NC
Laporte
J P
JP
Leon
A
A
Brantus
J F
JF
Miossec
P
P
D000328:Adult; D018952:Antigens, CD34 / Q000009:adverse effects / Q000276:immunology*; D001402:B-Lymphocytes; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D009061:Mouth Mucosa / Q000382:microbiology; D013280:Stomatitis / Q000139:chemically induced / Q000276:immunology; D013601:T-Lymphocytes; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018952:Antigens, CD34; D007166:Immunosuppressive Agents; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide